Prothrombotic platelet phenotype in major depression: Downregulation by antidepressant treatment

Journal of Affective Disorders

Volumn 159, Issue , 2014, Pages 39-45

  Lopez Vilchez, Irene ^a   Serra Millas, Montserrat ^b   Navarro, Victor ^b   Rosa Hernandez, M ^a   Villalta, Jaume ^b   Diaz Ricart, Maribel ^a   Gasto, Cristobal ^b   Escolar, Gines ^a   Galan, Ana M ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

Cardiovascular risk; Major depression; Platelets; Procoagulant profile; Prothrombotic phenotype; Selective serotonin reuptake inhibitor (SSRI)

Indexed keywords

ARACHIDONIC ACID; BLOOD CLOTTING FACTOR 5; ESCITALOPRAM; FIBRINOGEN; PHOSPHOLIPID; THROMBIN RECEPTOR; THROMBOPLASTIN; BIOLOGICAL MARKER; CITALOPRAM; SEROTONIN UPTAKE INHIBITOR;

ADULT; AGED; ARTICLE; BLOOD CLOTTING; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; FIBRIN FORMATION; FLOW CYTOMETRY; HUMAN; MAJOR DEPRESSION; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; THROMBOCYTE; THROMBOCYTE AGGREGATION; THROMBOCYTE VOLUME; THROMBOGENICITY; THROMBOSIS; TREATMENT DURATION; TREATMENT OUTCOME; VISCOELASTICITY; YOUNG ADULT; ADOLESCENT; BLOOD; DEPRESSIVE DISORDER, MAJOR; DRUG EFFECTS; PHYSIOLOGY; THROMBOCYTE ACTIVATION;

ADOLESCENT; ADULT; AGED; BIOLOGICAL MARKERS; BLOOD PLATELETS; CITALOPRAM; DEPRESSIVE DISORDER, MAJOR; DOWN-REGULATION; FEMALE; FLOW CYTOMETRY; HUMANS; MALE; MIDDLE AGED; PHENOTYPE; PLATELET ACTIVATION; SEROTONIN UPTAKE INHIBITORS; THROMBOSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84895820264     PISSN: 01650327     EISSN: 15732517     Source Type: Journal    
DOI: 10.1016/j.jad.2014.02.022     Document Type: Article

References (44)

1. L. Alberio, and G.L. Dale Platelet-collagen interactions: membrane receptors and intracellular signalling pathways Eur. J. Clin. Invest. 29 1999 1066 1076
2. ®)
3. C. Andrade, S. Sandarsh, K.B. Chethan, and K.S. Nagesh Serotonin reuptake inhibitor antidepressants and abnormal bleeding: a review for clinicians and a reconsideration of mechanisms J Clin. Psychiatry 71 2010 1565 1575
4. A. Ataoglu, and F. Canan Mean platelet volume in patients with major depression: effect of escitalopram treatment J. Clin. Psychopharmacol. 29 2009 368 371
5. D. Atar, A. Malinin, A. Pokov, L. van Zyl, N. Frasure-Smith, F. Lesperance, and V.L. Serebruany Antiplatelet properties of escitalopram in patients with the metabolic syndrome: a dose-ranging in vitro study Neuropsychopharmacology 32 2007 2369 2374 (Pubitemid 47587669)
6. J.T. Bigger, and A.H. Glassman The American Heart Association science advisory on depression and coronary heart disease: an exploration of the issues raised Cleve. Clin. J. Med. 77 3 2010 S12 S19
7. Y. Bismuth-Evenzal, Y. Gonopolsky, D. Gurwitz, I. Iancu, A. Weizman, and M. Rehavi Decreased serotonin content and reduced agonist-induced aggregation in platelets of patients chronically medicated with SSRI drugs J Affect. Disord. 136 2012 99 103
8. Y. Bismuth-Evenzal, N. Roz, D. Gurwitz, and M. Rehavi N-methyl-citalopram: A quaternary selective serotonin reuptake inhibitor Biochem. Pharmacol. 80 2010 1546 1552
9. R.M. Carney, and K.E. Freedland Depression, mortality, and medical morbidity in patients with coronary heart disease Biol. Psychiatry 54 2003 241 247 (Pubitemid 37267854)
10. R.M. Carney, K.E. Freedland, A.S. Jaffe, N. Frasure-Smith, F. Lesperance, D.S. Sheps, A.H. Glassman, C.M. Oconnor, J.A. Blumenthal, P.G. Kaufmann, and S.M. Czajkowski Depression as a risk factor for post-MI mortality J. Am. Coll. Cardiol. 44 2004 472 474
11. G.L. Dale Coated-platelets: an emerging component of the procoagulant response J. Thromb. Haemost. 3 2005 2185 2192 (Pubitemid 41727196)
12. F.J de Abajo, D. Montero, L.A. Rodriguez, and M. Madurga Antidepressants and risk of upper gastrointestinal bleeding Basic Clin. Pharmacol. Toxicol. 98 2006 304 310
13. 12 receptor by thiol reagents requires interaction with both extracellular cysteine residues, Cys17 and Cys270 Blood 101 2003 3908 3914 (Pubitemid 36857866)
14. G. Escolar, M. Diaz-Ricart, E. Gomez-Gil, M. Serra, C. Gasto, J. Bozzo, and A.M. Galan Serotonergic mechanisms: a potential link between affective disorders and cardiovascular risk Drugs Today (Barc.) 41 2005 721 743 (Pubitemid 43074782)
15. A.M. Galan, I. Lopez-Vilchez, M. Diaz-Ricart, F. Navalon, E. Gomez, C. Gasto, and G. Escolar Serotonergic mechanisms enhance platelet-mediated thrombogenicity Thromb. Haemost. 102 2009 511 519
16. L.D. Garfield, J.F. Scherrer, P.J. Hauptman, K.E. Freedland, T. Chrusciel, S. Balasubramanian, R.M. Carney, J.W. Newcomer, R. Owen, K.K. Bucholz, and P.J. Lustman Association of anxiety disorders and depression with incident heart failure Psychosom. Med. 76 2014 128 136
17. L. Gunther, S. Liebscher, M. Jahkel, and J. Oehler Effects of chronic citalopram treatment on 5-HT1A and 5-HT2A receptors in group- and isolation-housed mice Eur. J. Pharmacol. 593 2008 49 61
18. J. Honkola, E. Hookana, S. Malinen, K.S. Kaikkonen, M.J. Junttila, M. Isohanni, M.L. Kortelainen, and H.V. Huikuri Psychotropic medications and the risk of sudden cardiac death during an acute coronary event Eur. Heart J. 33 2012 745 751
19. D. Hoyer, J.P. Hannon, and G.R. Martin Molecular, pharmacological and functional diversity of 5-HT receptors Pharmacol. Biochem. Behav. 71 2002 533 554 (Pubitemid 34219205)
20. G. Jedlitschky, A. Greinacher, and H.K. Kroemer Transporters in human platelets: physiologic function and impact for pharmacotherapy Blood 119 2012 3394 3402
21. N.S. Key, A. Slungaard, L. Dandelet, S.C. Nelson, C. Moertel, L.A. Styles, F.A. Kuypers, and R.R. Bach Whole blood tissue procoagulant activity is elevated in patients with sickle cell disease Blood 91 1998 4216 4223 (Pubitemid 28261985)
22. C. Labos, K. Dasgupta, H. Nedjar, G. Turecki, and E. Rahme Risk of bleeding associated with combined use of selective serotonin reuptake inhibitors and antiplatelet therapy following acute myocardial infarction C.M.A.J 183 2011 1835 1843
23. M.J. Lambiase, L.D. Kubzansky, and R.C. Thurston Prospective study of anxiety and incident stroke Stroke 45 2014 438 443
24. F. Lesperance, N. Frasure-Smith, D. Koszycki, M.A. Laliberte, L.T. Van Zyl, B. Baker, J.R. Swenson, K. Ghatavi, B.L. Abramson, P. Dorian, and M.C. Guertin Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) trial JAMA 297 2007 367 379 (Pubitemid 46155798)
25. J.H. Lichtman, J.T. Bigger Jr., J.A. Blumenthal, N. Frasure-Smith, P.G. Kaufmann, F. Lesperance, D.B. Mark, D.S. Sheps, C.B. Taylor, and E.S. Froelicher Depression and coronary heart disease: recommendations for screening, referral, and treatment: a science advisory from the American Heart Association Prevention Committee of the council on cardiovascular nursing, council on clinical cardiology, council on epidemiology and prevention, and interdisciplinary council on quality of care and outcomes research: endorsed by the American Psychiatric Association Circulation 118 2008 1768 1775
26. G. Lippi, M. Montagnana, E.J. Favaloro, and M. Franchini Mental depression and cardiovascular disease: a multifaceted, bidirectional association Semin. Thromb. Hemost. 35 2009 325 336
27. I. Lopez-Vilchez, M. Diaz-Ricart, J.G. White, G. Escolar, and A.M. Galan Serotonin enhances platelet procoagulant properties and their activation induced during platelet tissue factor uptake Cardiovasc. Res. 84 2009 309 316
28. I. Lopez-Vilchez, A.M. Galan, M.R. Hernandez, C. Caballo, M. Roque, M. az-Ricart, J.G. White, and G. Escolar Platelet-associated tissue factor enhances platelet reactivity and thrombin generation in experimental studies in vitro Thromb. Res. 130 2012 e294 e300
29. M. Maes, P. Ruckoanich, Y.S. Chang, N. Mahanonda, and M. Berk Multiple aberrations in shared inflammatory and oxidative & nitrosative stress (IO&NS) pathways explain the co-association of depression and cardiovascular disorder (CVD), and the increased risk for CVD and due mortality in depressed patients Prog. Neuropsychopharmacol. Biol. Psychiatry 35 2011 769 783
30. E. Maurer-Spurej, C. Pittendreigh, and K. Solomons The influence of selective serotonin reuptake inhibitors on human platelet serotonin Thromb. Haemost. 91 2004 119 128 (Pubitemid 38120206)
31. A. ONeil, E.D. Williams, C.E. Stevenson, B. Oldenburg, M. Berk, and K. Sanderson Co-morbid cardiovascular disease and depression: sequence of disease onset is linked to mental but not physical self-rated health. Results from a cross-sectional, population-based study Soc. Psychiatry Psychiatr. Epidemiol. 47 2012 1145 1151
32. S. Offermanns Activation of platelet function through G protein-coupled receptors Circ. Res. 99 2006 1293 1304 (Pubitemid 44949665)
33. R. Oruch, E. Hodneland, I.F. Pryme, and H. Holmsen Psychotropic drugs interfere with the tight coupling of polyphosphoinositide cycle metabolites in human platelets: a result of receptor-independent drug intercalation in the plasma membrane? Biochim. Biophys. Acta 1778 2008 2165 2176
34. D.C. Purselle, and C.B. Nemeroff Serotonin transporter: A potential substrate in the biology of suicide Neuropsychopharmacology 28 2003 613 619
35. J.A. Ramos-Brieva, and A. Cordero-Villafafila A new validation of the Hamilton Rating Scale for Depression J. Psychiatr. Res. 22 1988 21 28
36. M. Rehavi, Z. Jerushalemi, A. Aviv, N. Laor, E. Podliszewski, L. Karp, S. Shavit, and R. Weizman Interaction between antidepressants and phosphoinositide signal transduction system in human platelets Biol. Psychiatry 33 1993 40 44 (Pubitemid 23042679)
37. L.B. Rosenberg, W. Whang, D. Shimbo, A. Shah, P.A. Shapiro, and K.W. Davidson Exposure to tricyclic antidepressants is associated with an increased risk of incident CHD events in a population-based study Int. J. Cardiol. 145 2010 124 125
38. D. Shimbo, J. Child, K. Davidson, E. Geer, J.I. Osende, S. Reddy, A. Dronge, V. Fuster, and J.J. Badimon Exaggerated serotonin-mediated platelet reactivity as a possible link in depression and acute coronary syndromes Am. J. Cardiol. 89 2002 331 333 (Pubitemid 34113797)
39. C. Stratz, D. Trenk, H.S. Bhatia, C. Valina, F.J. Neumann, and B.L. Fiebich Identification of 5-HT3 receptors on human platelets: increased surface immunoreactivity after activation with adenosine diphosphate (ADP) and thrombin receptor-activating peptide (TRAP) Thromb. Haemost. 99 2008 784 786 (Pubitemid 351694238)
40. C.B. Taylor, M.E. Youngblood, D. Catellier, R.C. Veith, R.M. Carney, M.M. Burg, P.G. Kaufmann, J. Shuster, T. Mellman, J.A. Blumenthal, R. Krishnan, and A.S. Jaffe Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction Arch. Gen. Psychiatry 62 2005 792 798 (Pubitemid 41002762)
41. W. Whang, and K.W. Davidson Is it time to treat depression in patients with cardiovascular disease? Circulation 120 2009 99 100
42. W. Whang, L.D. Kubzansky, I. Kawachi, K.M. Rexrode, C.H. Kroenke, R.J. Glynn, H. Garan, and C.M. Albert Depression and risk of sudden cardiac death and coronary heart disease in women: results from the Nur Health Study J. Am. Coll. Cardiol. 53 2009 950 958
43. M. Yamauchi, T. Miyara, T. Matsushima, and T. Imanishi Desensitization of 5-HT2A receptor function by chronic administration of selective serotonin reuptake inhibitors Brain Res. 1067 2006 164 169 (Pubitemid 43133085)
44. E. Ziu, C.P. Mercado, Y. Li, P. Singh, B.A. Ahmed, S. Freyaldenhoven, S. Lensing, J. Ware, and F. Kilic Down-regulation of the serotonin transporter in hyperreactive platelets counteracts the pro-thrombotic effect of serotonin J. Mol. Cell. Cardiol. 52 2012 1112 1121